ClinicalTrials.gg
RecruitingNCT04742998DAPADAF-EUpdated Jul 24, 2023

Task of Acoustic-phonetic Decoding on Anatomic Deficits in Paramedical Assessment of Speech Disorders for Patients Treated for Oral or Oropharyngeal Cancer

An observational study in Speech Intelligibility, sponsored by University Hospital, Toulouse. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by University Hospital, Toulouse · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 5 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
116
Ages
18 Years and older
Sex
All
01

Study summary

The bridging of the gap between speech production and perception by the interlocutor would be made possible by the use of a more suitable and automatic task. An acoustic-phonetic decoding test (or DAP in French, i.e. the production of isolated pseudo-words in repetition or reading), created within the framework of the The French National Cancer Institute (InCA) C2SI project, avoids the effects of cognitive restoration by the interlocutor. An automatic score from the DAP would lead to an overall score per patient, but also to scores specific to each phonetic segment, to be correlated with the analytical scores from each anatomical oropharyngeal segment.

The study hypothesis is that the automatic processing of an acoustic-phonetic decoding task during the assessment in current practice is a valid and reliable tool for diagnosing oropharyngeal analytical and dynamic deficits by highlighting deficient linguistic units.

The study hypothesis is that the automatic processing of an acoustico-phonetic decoding task during the assessment in current practice is a tool for diagnosing oropharyngeal analytical and dynamic deficits by highlighting deficient linguistic units.

Read the detailed description

Fifth cancer in terms of incidence in France, tumor pathologies of the upper aero-digestive tract, due to their location, impact the speech abilities of affected subjects. Speech therapy in paramedical clinical assessments consist of two parts.

  • The analytical part to highlight the anatomical and dynamic deficits of segments involved in speech.
  • The functional part characterizes the pathophysiological impact by means of an "ear" assessment.

The link between anatomy and functional speech deficit is very close in oncology (the location and the size of the tumor, the structural changes due to the treatment who modify the oropharyngeal dynamics and the mechanisms involved in the production of the speech), but the correlation is weak between functional intelligibility scores and analytical motor scores. Indeed, the perception of speech by a human listener is not a simple "recording" of the production, but a representation of this production after implementation of individual mechanisms for restoring the acoustic information linked to the lexicon or to the context by the listener. The listener's degree of familiarity with the speaker or his pathology is also a source of variability.

The bridging of the gap between speech production and perception by the interlocutor would be made possible by the use of a more suitable and automatic task. An acoustic-phonetic decoding test (or DAP in French, i.e. the production of isolated pseudo-words in repetition or reading), created within the framework of the InCA C2SI project, avoids the effects of cognitive restoration by the interlocutor. An automatic score from the DAP would lead to an overall score per patient, but also to scores specific to each phonetic segment, to be correlated with the analytical scores from each anatomical oropharyngeal segment.

The study hypothesis is that the automatic processing of an acoustic-phonetic decoding task during the assessment in current practice is a valid and reliable tool for diagnosing oropharyngeal analytical and dynamic deficits by highlighting deficient linguistic units.

02

Conditions studied

  • Speech Intelligibility

Browse trials for

Keywords

  • speech deficit
  • tumor pathologies of the upper aero-digestive tract
03

In context

Speech Intelligibility

32 studies on the registry are indexed under Speech Intelligibility; 10 are open to participants now.

Browse Speech Intelligibility studies →

Lead sponsor

University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All site have an active group of person allowing a feasibility of recruitment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged at least 18 years old and benefiting from a social security scheme
  • Native French-speaking patients
  • Patients treated for cancer of the oral cavity or oropharynx (surgical and / or radiotherapy and / or chemotherapy treatment)
  • Patients in clinical remission for at least 6 months (chronic nature and stability of the disorders)
  • All tumor sizes according to the tumor (T), node (N), and (M) categories (TNM classification) (T1 to T4)
  • Patients with a perceptible speech disorder in a conversational situation or not (to allow the determination of fine deficits)
  • Patients who do not object to carrying out the research

Exclusion criteria

Exclusion Criteria:

  • Patients with an associated pathology potentially responsible for speech or fluency disorders (joint, speech and language disorders of developmental, organic or functional origin, voice disorders of organic or functional origin, stammering , stammering, fluency disturbances, speech disturbances of neurological origin)
  • Patients reporting an auditory complaint and not having a hearing aid
  • Inability to provide the person with enlightened information and to ensure the subject's compliance because of impaired physical and / or psychological health,
  • Patients participating in another research including an exclusion period still in progress.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
116 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients treated for an oral or oropharyngeal tumor for at least 6 months

    Patients treated for an oral or oropharyngeal tumor for at least 6 months

    Other: Acoustic-phonetic decoding task (DAP)

Interventions

  • OtherAcoustic-phonetic decoding task (DAP)

    Completion of speech-related quality of life autoquestionnaires Routine speech assessment Acoustic-phonetic decoding task (DAP) two lists of 16 pseudo-words

06

What researchers measure

Primary outcomes

  1. Correlation coefficient

    Correlation coefficient between he automatic score by phoneme class from the DAP and the score for each oropharyngeal anatomical segment from muscle testing

    Time frame: Day 1

Secondary outcomes

  1. Human perceptual score - Direct transcription

    the speech therapist will transcribe the pseudo-word he thinks he has recognized immediately after the subject says it, using software installed on the examination computer. A perceptual score of linguistic traits of average difference (between expected production and perception by the speech therapist) by phoneme will then be determined.

    Time frame: Day 1

  2. Human perceptual score - jury transcription

    Audio recordings of the task will be made. A perceptual score of linguistic traits of average difference (between expected production and perception by the jury) by phoneme will then be determined

    Time frame: Day 1

  3. Head and Neck Carcinologic Handicap Index (HNCHI)

    Correlation between HNCHI and scores from the DAP

    Time frame: Day 1

07

Study locations

2 of 3 sites recruiting
08

References and documents

Publications

  • Balaguer M, Farinas J, Fichaux-Bourin P, Puech M, Pinquier J, Woisard V. Validation of the French Versions of the Speech Handicap Index and the Phonation Handicap Index in Patients Treated for Cancer of the Oral Cavity or Oropharynx. Folia Phoniatr Logop. 2020;72(6):464-477. doi: 10.1159/000503448. Epub 2019 Nov 15. PubMed 31734664 ↗
  • Balaguer M, Champenois M, Farinas J, Pinquier J, Woisard V. The (head and neck) carcinologic handicap index: validation of a modular type questionnaire and its ability to prioritise patients' needs. Eur Arch Otorhinolaryngol. 2021 Apr;278(4):1159-1169. doi: 10.1007/s00405-020-06201-6. Epub 2020 Jul 14. PubMed 32666294 ↗
  • Lalain M, Ghio A, Giusti L, Robert D, Fredouille C, Woisard V. Design and Development of a Speech Intelligibility Test Based on Pseudowords in French: Why and How? J Speech Lang Hear Res. 2020 Jul 20;63(7):2070-2083. doi: 10.1044/2020_JSLHR-19-00088. Epub 2020 Jun 29. PubMed 32598209 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04742998
Collaborators
Laboratoire parole et langage, Laboratoire Information Avignon université, IRIT - Institut de Recherche en Informatique de Toulouse
Responsible party
Sponsor
First posted
Feb 8, 2021
Start date
Oct 22, 2021
Primary completion
Oct 22, 2024 (estimated)
Completion
Oct 22, 2024 (estimated)
Last update
Jul 24, 2023

Study contacts

Clémence DEVOUCOUX
Contact
devoucoux.c@chu-toulouse.fr
06.50.72.24.85 ext. +33
Anaïs GALTIER
Contact
Galtier.a@chu-toulouse.fr
05. 67. 77. 18 .70 ext. +33
Clémence DEVOUCOUX
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion